anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Good postural stability control is dependent upon the complex integration of incoming sensory information (visual, somatosensory, vestibular) with neuromotor responses that are constructed in advance of a voluntary action or in response to an unexpected perturbation.
AIMS: To examine whether differences exist in how sensory inputs are used to control standing balance in children with and without Prader-Willi syndrome (PWS).
METHODS AND PROCEDURES: In this cross-sectional study, 18 children with PWS and 51 children categorized as obese but without PWS (without PWS) ages 8-11 completed the Sensory Organization Test®. This test measures the relative contributions of vision, somatosensory, and vestibular inputs to the control of standing balance. The composite equilibrium score (CES) derived from performance in all sensory conditions, in addition to equilibrium scores (EQs) and falls per condition were compared between groups.
OUTCOMES AND RESULTS: The CES was lower for children with PWS compared to children without PWS (M=53.93, SD=14.56 vs. M=66.17, SD=9.89, p = .001) while EQs declined in both groups between conditions 1 and 4 (F (1.305, 66.577) = 71.381, p < .001). No group differences in the percent of falls were evident in condition 5 but more children with PWS fell in condition 6 (χ2 (1) = 7.468, p = .006). Group differences in frequency of repeated falls also approached significance in conditions 5 (χ2 (3) = 4.630, p = .099) and 6 (χ2 (3) = 5.167, p = .076).
CONCLUSIONS AND IMPLICATIONS: Children with PWS demonstrated a lower overall level of postural control and increased sway when compared to children with obesity. Both the higher incidence and repeated nature of falls in children with PWS in conditions 5 and 6 suggest an inability to adapt to sensory conditions in which vestibular input must be prioritized. Postural control training programs in this population should include activities that improve their ability to appropriately weight sensory information in changing sensory environments, with a particular focus on the vestibular system. WHAT DOES THIS STUDY ADD?: This study shows that children with PWS demonstrate a lower level of postural stability. The results suggest that children with PWS show inability to adapt to sensory conditions that require prioritizing vestibular information to maintain postural control. This information can be used to help guide training programs in this population.
Particles of a (primary) oil-in-hydrophilic liquid emulsion containing a thickening agent in the hydrophilic liquid phase are encapsulated by forming a secondary emulsion comprising the said primary emulsion dispersed in a coacervating medium comprising an aqueous dispersion of at least two coacervating polymers, at least one of which is a hydrophilic colloid and at least one of which is a linear macromolecular synthetic polymer and causing the polymers to coacervate and thus coat the dispersed primary emulsion particles by altering the pH or by dilution with water.  Suitable thickening agents are: acacia, tragacanth, methyl- and carboxymethyl-cellulose, magnesium aluminium silicate, polyglycols, glycerin and syrups.  As hydrophilic colloids there are mentioned gelable and nongelable hydrophilic colloids e.g. gelatine, agar, albumen, alginates, deacetylated chitin, acacia, starch and fibrinogen.  Suitable polymers are those whose structure comprises both lipophilic and hydrophilic units, e.g. styrene-maleic acid amide and methyl-vinyl ether-maleic acid copolymers, polymethacrylic acid, carbohydrate acetate phthalates and (preferably) hydrolysed styrene-maleic anhydride copolymers and modifications thereof, in particular those of general formula [-R-R1-]n, wherein R represents lipophilic polymer units of which more than 70% are styrene residues and R1 represents hydrophilic units of which more than 50% are maleic acid residues. Solubilizing agents may be added to increase the concentration of polymer, e.g. solvents and polysaccharides, e.g. alginates, pectins, methyl- and carboxymethyl-cellulose and Irish moss derivatives. Either or both phases of the primary emulsion may contain dissolved or suspended "active" ingredients which render the product of the invention useful as sustained release fertilizers, plant growth regulants, bactericides, and pesticides, as food additives, cosmetic ingredients and medicines.  Specific examples include: (a) mineral oil-in-caffeine aqueous suspension in gelatine and styrene-maleic acid copolymer, and (b) corn oil-in-aqueous rotenone suspension in fibrinogen and cellulose acetate phthalate.  Specification 751,600 is referred to.
Clinicians in the dermatology departments will identify eligible participants at the time of initial consultation. An information leaflet will be provided and details of the participants who are interested in participating will be forwarded to the research team to check eligibility prior to the procedure. Prior to the procedure relevant clinical information will be recorded in the Case Report Form (CRF) including demographic data, tumour site, tumour size, size of tumoural ulceration and type of wound closure. Histopathological data will be collected on tumour type when it is reported. Participants and clinicians will be asked whether they would agree for the patients to be randomised to no antibiotics, topical treatment eg. InadineTM dressings, a short course of antibiotics or a longer course of antibiotics in a future RCT. Following the procedure, information about whether oral antibiotics were prescribed will be recorded on a standardized CRF. All participants will be provided with the same information leaflet detailing standard post-operative advice and further care will be as per each centre's 'standard clinical care' which will also be recorded.

If participants are diagnosed with SSI they will be asked to take a photo of their wound on a camera phone and then to share the photo with the Cardiff University Centre for Trials Research (CTR) via email. Reeves et al. have described this practice as a 'wound selfie' and report that the term is readily understood. If participants are not able to take of photo of their wound then they will be invited to attend the department to have a photograph taken by medical photography. All participants will be sent a questionnaire by the research team four weeks following their procedure to enquire specifically whether the participant was diagnosed and treated for wound infection. These data will be collected by Cardiff University CTR who will co-ordinate the study.

Additionally, all participants at University Hospital of Wales will have a surface swab taken from their ulcerated skin tumour and these will be analysed in the Public Health Wales laboratory at the University of Wales, Cardiff. The aim of this aspect of the study is to identify the most common organisms that colonise ulcerated tumours. Previous studies have commented on growth from ulcerated tumours, however it is not clear if this was conducted in a research laboratory setting. This will help to guide antibiotic choice in a future randomized controlled trial.
Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment. Monoclonal anti-CD20 antibody, rituximab, in combination of CHOP chemotherapy (R-CHOP) is widely used with favourable results. Although more than half of patients achieve long-term remission, many are not cured with this immunotherapy. Decreased CD20 expression has been postulated to be one of the most important contributing to rituximab resistance. Moreover, R-CHOP therapies are sometimes ineffective, and new treatment strategies based notably on host immune responses modulation are being explored. Among them, programmed cell death ligand 1 (PD-L1) protein was identified as a potent predicting biomarker in DLBCL. Exosomes are small membrane vesicles secreted by several cell types during exocytic fusion of multivesicular bodies with the plasma membrane. Many cancer cells have been shown to secrete exosomes in greater amounts than normal cells. Exosome secretion may contribute to drug resistance. Indeed, exosome release from B-cell Non-Hodgkin Lymphoma (B-NHL), by the expression of CD20, has been suggest to act as decoy targets upon rituximab exposure, allowing lymphoma cells to escape from humoral immunotherapy. Finally, as exosome composition seems to be cell and tissue specific, they are highly suitable to serve as diagnostic markers.

Our hypothesis is that high expression of the immunotherapeutic targets (CD20, PD-L1) on exosomes derived from aggressive or resistant B-NHL may allow tumor cells to escape therapeutic antibodies, and thus contribute in vivo to therapeutic resistance. For this objective, we will used exosomes derived from DLBCL human cells and exosomes isolated from plasma of DLBCL patients. We will analyze, on these microvesicles, CD20 and PDL-1 expression in function of DLBCL sub-types and outcome of patients. Moreover, exosome capacity to interfere with immunotherapy will be also studied from in vitro and in vivo (xenografts) models.
Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
FIELD: medicine. SUBSTANCE: invention relates to use of intensive therapy for exogenous and endogenous detoxification of organism. Method of invention consists in using new device for preparing high-quality sodium hypochlorite solutions, namely flow-type electrolyzer with titanium electrodes promoted by microquantities of platinum and having roughness ratio no less than 200. Interelectrode distance ranges from 0.2 to 0.8 mm. Flow velocity of physiological solution is 100 to 400 ml/min. Current density is 20 to 100 (advantageously 10-20) mA/cm. Combination of the above-listed factors ensures preparing high-purity (in particular, not containing noxious sodium chlorate impurities) and sterile sodium hypochlorite solutions. EFFECT: eliminated effect of noxious impurities on immediate and delayed results of treatment of various pathologies associated with exogenous and endogenous detoxification. 4 cl, 1 dwg
Patients will be offered seven individual sessions of virtual reality therapy and two booster sessions conducted by a skilled therapist. In the initial phase of treatment, the participants create a virtual avatar that corresponds to their visual perception of the source of their voice. The therapist initiates, encourages and supports a dialogue between the participant and the avatar by alternating between talking as the avatar and as a supportive therapist. The therapy sessions last 50 minutes of which around 15 minutes is spent in dialogue with the avatar. The remaining 30 minutes will be used on preparing the patient for the confrontation with the avatar, evaluating on the interaction with the avatar, and use general cognitive behavioral techniques to reduce the auditory hallucination. The treatment is conducted with the use of virtual reality, so the participant will wear VR headset during treatment and watch and talk with the avatar shown in front of him or her.
All homeless adults, aged 18 years and over, who visit the CANCERLESS pilot sites will be asked to participate (convenience sampling). We define individuals as being homeless if they fall under one of the categories listed in the European typology of homelessness and housing exclusion.
Premenstrual symptom scale will be applied to the participants who volunteered to participate in the study. Aromatherapy will be applied to people with a premenstrual symptom score exceeding 110. 3 groups will be formed from people with pms symptoms. 1st group will receive Bergamot essential oil, 2nd group will receive Grapefruit essential oil, 3rd group (placebo group) will receive sweet almond oil. Selected women will be allowed to smell 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. The aromatic oil will be put 3 drops on a cotton ball and the participants will smell it. Participants will be allowed to inhale the scent for 30 minutes in the fowler position at a distance of 15 cm.
From recent studies, it has emerged that the gut microbiota is a possible responsible for the stimulation of the innate immune response and its role in the pathogenesis of autoimmune diseases has been deepened. Several clinical studies, in fact, support the existence of a connection between changes in the commensal intestinal microbiota ("dysbiosis") and autoimmune diseases. It has been seen that also ocular conditions like chalaziosis and uveitis are tied to dysbiosis. In addition, in a recent study probiotics were found to be safe and effective in the treatment of chalaziosis in children. Other eye conditions that may be affected by changes in the gut microbiome are dry eye syndrome and blepharitis. Under these conditions, a reduction in globet cells has often been noted. These cells produce the mucins present on the ocular surface, and therefore, their reduction involves the production of a thin and ineffective tear film. Therefore, the study will cover patients with blepharitis (both adults and children), treated with specific probiotics to be taken daily. Patients will then undergo a full ophthalmological examination each week for the first month, and then monthly until complete recovery for at least 6 months. In addition, at the time of enlistment and complete recovery, after venous sampling, the following biomarkers will be analyzed with cytometer and ELISA: TNFα and lymphocyte subpopulations. With this study, therefore, the aim is to define the possible positive impact of probiotics on patients with blepharitis.
<P>PROBLEM TO BE SOLVED: To provide a composition of cyclopamine which achieves good treatment effects on many diseases having a uniform characteristic related to obstruction of cell differentiation such as an ordinary disease of psoriasis related to disorder of cell differentiation.  <P>SOLUTION: The treating composition includes, in a suitable pharmaceutical carrier, cyclopamine and corticosteroid which carry out differentiation of tumor cells and induction of apoptosis even in not only base-cell carcinoma but also other ecphyma. Cyclopamine can dissolve in ethanol or other suitable solvents and mix with the suitable pharmaceutical carrier depending on a desired application style. For local application, cyclopamine can be dissolved in ethanol or another suitable solvent and mixed with a suitable base cream, ointment or gel. Then, cyclopamine can be adsorbed on a skin patch.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The disclosure provides compositions and methods for high-efficiency genome editing in mammals. In some aspects, the disclosure provides guide RNA-retron cassettes, RNA-guided nuclease (e.g., Cas9)-reverse transcriptase fusion protein encoding cassettes, and vectors comprising the cassettes. Also provided are mammalian host cells that have been transfected with the vectors. In other aspects, guide-retron donor DNA molecules are provided. In some other aspects, methods for genome editing in mammals and the screening of genetic loci are provided. In further aspects, methods and compositions are provided for the prevention or treatment of genetic diseases and for other applications. Kits for genome editing and screening are also provided.
Dose Selection—SEROQUEL XR should be administered once daily, preferably in the evening. The recommended initial dose is 300 mg/day. Patients should be titrated within a dose range of 400 mg/day – 800 mg/day depending on the response and tolerance of the individual patient [see Clinical Studies (14.1)]. Dose increases can be made at intervals as short as 1 day and in increments of up to 300 mg/day. The safety of doses above 800 mg/day has not been evaluated in clinical trials. 

Maintenance Treatment—A maintenance trial in adult patients with schizophrenia treated with SEROQUEL XR has shown this drug to be effective in delaying time to relapse in patients who were stabilized on SEROQUEL XR at doses of 400 mg/day to 800 mg/day for 16 weeks. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.1)].
Subjects will be enrolled in a staggered manner in up to 5 dose levels (provisional dose levels of 3, 6, 12, 20 and 28µg). All subjects will receive a single dose of CVSQIV on Day 1.
This is a Phase 4, multi center, open-label, assessor blinded, switch study of infliximab in patients with active rheumatoid arthritis who are receiving methotrexate and are having an inadequate response to their current treatment with etanercept or adalimumab. The last dose of etanercept must have been at least 1 week but not more than 2 weeks prior to the first infliximab study infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to the first infliximab study infusion. The study will be conducted for 30 weeks and will include 200 patients. All eligible patients will receive 3 mg/kg infliximab infusions (drug given into a vein) at weeks 0, 2, and 6 and every 8 weeks thereafter, if they achieve a European League Against Rheumatism (EULAR) response on their current dose of infliximab. Patients who do not achieve a EULAR response will increase their dose from 3mg/kg to 5 mg/kg at week 14. Patients who do not achieve a EULAR response at week 22 will increase from either 3 mg/kg to 5 mg/kg or from 5mg/kg to 7 mg/kg. The last study infusion will take place at week 22. The last study visit for effectiveness evaluations will take place at week 26. A week 30 follow-up visit will be performed for adverse events and tuberculosis evaluations, health economics assessments, and review of concomitant medications. All patients who end the study early will be required to complete all assessments. Patients will receive 3 mg/kg infliximab infusions at weeks 0, 2, and 6. If patients achieve European League Against Rheumatism (EULAR) response, they will remain on their current dose. Patients who do not demonstrate a EULAR response will increase their infliximab dose from 3 mg/kg to 5 mg/kg at week 14. At week 22, patients will also increase their infliximab dose from 3 mg/kg to 5mg/kg or from 5 mg/kg to 7mg/kg if they do not demonstrate a EULAR response.
The present invention relates to olive fruit tea and a preparation method thereof, which belongs to the technical field of the preparation of health care tea. The present invention aims to solve the technical problem of the olive fruit tea which contains no tea leaves and has the functions of health care and green environmental protection. The present invention has the main following technical scheme for solving the technical problem: complete fresh olive fruit is flattened by beating, cleaned and prepared into the olive fruit tea. The present invention is characterized in that the olive fruit is dried and then prepared into the olive fruit tea which simultaneously contains fragmented blocks of dry olive pulp, dry olive core and dry olive kernels. The olive fruit tea can contain octagon, chrysanthemum and licorice. The preparation method for the olive fruit tea mainly comprises the steps of flattening by beating, flushing, soaking in salt water, soaking in clear water, drying by draining, soaking in filter liquid, drying, stir-frying in a pot, sorting, redrying, packaging at normal temperature, etc., and 5kg of olive fresh fruit is used as an example, 900g of dry olive fruit tea is obtained after the processes are carried out. The olive fruit tea has the advantages of grey color, flaky shape and fragrant fruit flavor; the olive fruit tea is suitable for being drunk as tea, and can also be used as flavoring agents for cooking.
A method for controlling the formation of a microemulsion of fluorinated oils and water is disclosed. In particular, the addition of mixtures of fluorinated and hydrogenated surfactant to fluorinated oil and water is used to create a fluorinated oil microemulsion. The degree of hydrophilicity of the selected hydrogenated surfactant controls the temperature at which the microemulsion forms. The amphiphilic strength of the selected hydrogenated surfactant controls the concentration of fluorinated surfactant required for microemulsification of the fluorinated oil and water. As shown in figure 4, in forming a microemulsification containing water, perfluorodecalin, zonyl FSO-100(n-alkyl polyglycol ether with a perfluorinated alkyl chain) and C12E1 (hydrogenated surfactant produced by reacting C12, alkanol with 1 mol of ethylene oxide), the addition of increased concentrations of C12E1, lowers the temperature at which the microemulsion forms. The microemulsions are useful in treating body organs and delivering medicaments.
Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
This is a compassionate use protocol for participants who failed induction chemotherapy + Vaccine on previous trials. These participants then went on to high dose BEAM chemotherapy and transplant, then received idiotype vaccine therapy at 3 months post transplant. Vaccine was given monthly x 4 series, with a fifth series given 12 weeks after the fourth. Participants were then followed annually until progression or death with standard staging.
The invention relates to the technical field of medicines, in particular to a tea bag for treating xerophthalmia, which is prepared from the following raw material medicines in parts by weight: 2 parts of radix pseudostellariae, 2 parts of dendrobium, 1 part of adenophora tetraphylla, 2 parts of wolfberry fruit, 2 parts of radix ophiopogonis, 1 part of butterflybush flower, 2 parts of albizzia julibrissin and 3 parts of cicada fungus. The invention also comprises the application of the bulk drug in the preparation of the medicine for treating xerophthalmia and the preparation method of the tea bag for treating xerophthalmia. Its advantages are: 1. the selected raw material medicines have wide sources, all the raw material medicines accord with the compatibility principle of 'monarch, minister, assistant and guide', and the traditional Chinese medicine is safe and has no toxic or side effect. 2. The invention adopts a targeted therapy to treat patients, and the experimental result proves that: the treatment efficiency is high, the patient acceptance is high, and the recurrence rate is low. 3. The proportion of the traditional Chinese medicine components is screened by tests, and the effect is obvious. 4. The preparation method is simple and convenient in preparation process, has exact curative effect on xerophthalmia patients, and has good application prospect.
Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. A large body of existing data suggests that exercise improves cardiovascular and cerebrovascular functioning and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. Therefore, our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. RAATE-MCI is a 52-week randomized controlled trial that will assign insufficiently active African American adults aged 60 and older to one of two groups: a physical activity intervention or a successful aging (active control) group. Outcome measures will be collected at baseline, 24-,and 52-weeks. 144 older African American adults will be recruited.

Intervention will consist of one of two groups: a 150 minutes of physical activity (PA) per week or successful aging (SA) group. All physical activity and successful aging group sessions will be conducted at Pennington Biomedical or at local community facilities that include branches of the YMCA and community centers.